Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 19, 2026

Procter & Gamble Q2 Earnings Preview: Buy Now or Stay Cautious?

View original at finance.yahoo.com
Procter & Gamble Q2 Earnings Preview: Buy Now or Stay Cautious? The Procter & Gamble Company PG, also known as P&G, is set to report second-quarter fiscal 2026 results on Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Existing shareholders may consider holding the stock for its stability and long-term fundamentals, while closely monitoring execution on innovation, pricing and productivity initiatives

    80% confidence
  • Our model predicts year-over-year organic sales growth of 1% for PG in the second quarter of fiscal 2026

    80% confidence
  • PG has a trailing four-quarter earnings surprise of 2.3%, on average

    80% confidence
  • Management predicts a commodity cost headwind of $100 million after tax for fiscal 2026

    80% confidence
  • Management repeatedly emphasizing that sustainable growth will come from superior performance rather than price-led tactics

    80% confidence
  • Our model predicts a year-over-year core gross margin decline of 50 bps for the fiscal second quarter

    80% confidence
  • We expect organic sales for both the Fabric & Home Care, and and Baby, Feminine & Family Care segments to be flat year over year

    80% confidence
  • Management expects higher costs from tariffs of $400 million, after-tax, for fiscal 2026

    80% confidence
  • Management acknowledged heightened promotional activity in categories, such as Fabric Care, Baby Care and Oral Care, particularly in the United States and Europe

    80% confidence
  • Procter & Gamble has an Earnings ESP of -0.82% and a Zacks Rank #4 (Sell)

    80% confidence
  • Management cautioned that tariff relief may be offset by pricing rollbacks if duties are reduced

    80% confidence
  • For new investors, waiting for clearer signs of margin recovery or a more attractive valuation could be prudent

    80% confidence
  • The consensus mark for PG's earnings is pegged at $1.87 per share, indicating a 0.5% decline from the year-ago quarter's actual

    80% confidence
  • We expect the core operating margin to fall by 80 bps in the quarter

    80% confidence
  • The Zacks Consensus Estimate for fiscal second-quarter revenues is pegged at $22.23 billion, indicating a 1.6% rise from the prior-year quarter's reported figure

    80% confidence
  • Management anticipates an after-tax headwind of about $250 million for fiscal 2026 due to modestly higher net interest expenses and an increased core effective tax rate compared with the previous year

    80% confidence
  • Our model estimates organic sales growth of 2% each for the Beauty and Health Care segments, and 4% for the Grooming segment

    80% confidence
  • The consensus mark for earnings has moved down by a penny in the past 30 days

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com